Repligen Corp (RGEN) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Repligen Corp (RGEN) stock forecast summary
On Oct. 16, 2026, RGEN is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
Repligen Corp is a large-cap company with a market capitalization of $10.39B. It ranks number 13 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its P/E Ratio of 266.89x is the highest of the 15 peers that report one.
For RGEN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 62.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 54.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, RGEN included.
Follow RGEN freeRGEN price chart and AI forecast
How RGEN ranks among 5171 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Repligen Corp (RGEN) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | RGEN | Rank |
|---|---|---|
| Market Cap | $10.39B | 13/60 |
| P/E Ratio | 266.89x | 1/15 |
| P/B Ratio | 4.92x | 25/49 |
| EPS | $0.69 | – |
| Book Value/Share | $37.42 | – |
| Revenue/Share | $13.91 | – |
| FCF/Share | $1.98 | – |
Profitability & Margins
| Metric | RGEN | Rank |
|---|---|---|
| ROE | 2.0% | 14/47 |
| ROA | 1.4% | 14/50 |
| ROIC | 2.3% | 14/53 |
| Gross Margin | 53.8% | 19/24 |
| Operating Margin | 8.2% | 12/40 |
| Net Margin | 5.3% | 13/37 |
| EBT Margin | 6.6% | 13/42 |
| Tax Rate | 20.4% | – |
Financial Health
| Metric | RGEN | Rank |
|---|---|---|
| Current Ratio | 9.05x | 18/59 |
| Quick Ratio | 7.64x | 4/28 |
| D/E Ratio | 0.40x | 26/53 |
| Financial Leverage | 1.40x | 26/52 |
| Interest Coverage | 2.3x | 12/37 |
| Working Capital | $1.07B | 12/59 |
Cash Flow
| Metric | RGEN | Rank |
|---|---|---|
| Operating Cash Flow | $135M | 14/57 |
| Free Cash Flow | $112M | 13/50 |
| Capital Spending | -$23M | 38/50 |
| OCF Growth YoY | 2.1% | 11/16 |
| FCF Growth YoY | 2.8% | 8/15 |
| FCF/Sales | 14.3% | 13/32 |
| CapEx/Sales | 2.9% | 20/32 |
Operational Efficiency
| Metric | RGEN | Rank |
|---|---|---|
| Asset Turnover | 0.27x | 22/36 |
| Receivables Turnover | 5.0x | 14/24 |
| Inventory Turnover | 1.9x | 17/23 |
| Fixed Assets Turnover | 4.7x | 16/37 |
| Days Sales Outstanding | 73 days | 11/24 |
| Days Inventory | 188 days | 7/23 |
| Payables Period | 33 days | 21/26 |
| Cash Conversion Cycle | 228 days | 3/18 |
Income Statement
| Metric | RGEN | Rank |
|---|---|---|
| Total Revenue | $785M | 12/37 |
| Operating Income | $65M | 13/54 |
| Net Income | $42M | 13/50 |
| R&D Expense | $56M | 52/56 |
| SG&A Expense | $301M | 11/22 |
| Cost of Goods Sold | $362M | 10/26 |
Dividend & Shareholder Information
| Metric | RGEN | Rank |
|---|---|---|
| Shares Outstanding | 56M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.20B | 40.7% of assets |
| Cash & Short-term Investments | $607M | 20.6% of assets |
| Accounts Receivable | $158M | 5.3% of assets |
| Inventory | $187M | 6.3% of assets |
| Total Liabilities | $838M | 28.4% of assets |
| Short-term Debt | $99M | 3.4% of assets |
RGEN quarterly financials and insider trading
Repligen Corp (RGEN) industry peers
Companies classified under the same SEC industry code as Repligen Corp (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| RGEN Repligen Corp | ▶ | $10.39B |
| AMGN Amgen Inc | ▼ | $233.82B |
| GILD Gilead Sciences, Inc. | ▲ | $193.67B |
| MRNA Moderna, Inc. | ▲ | $94.42B |
| ARGX Argenx Se | ▼ | $50.69B |
| RVMD Revolution Medicines, Inc. | ▲ | $40.57B |
| BIIB Biogen Inc. | ▼ | $34.13B |
| BNTX Biontech Se | ▲ | $22.18B |
| EXEL Exelixis, Inc. | ▶ | $15.42B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.92B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.83B |
| TECH Bio-Techne Corp | ▼ | $11.37B |
| IBRX Immunitybio, Inc. | ▲ | $10.60B |
| QGEN Qiagen N.V. | ▶ | $10.02B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.77B |
| PCVX Vaxcyte, Inc. | ▲ | $9.71B |
| TWST Twist Bioscience Corp | ▲ | $9.06B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.99B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.67B |
| IMVT Immunovant, Inc. | ▲ | $5.68B |
| KOD Kodiak Sciences Inc. | ▲ | $5.54B |
| CGON Cg Oncology, Inc. | ▲ | $5.31B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.95B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.76B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.83B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.79B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.12B |
| DNLI Denali Therapeutics Inc. | ▼ | $2.81B |
| LIFE Atyr Pharma Inc | ▲ | $2.45B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.42B |
| ADMA Adma Biologics, Inc. | ▼ | $2.39B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.23B |
| NVAX Novavax Inc | ▲ | $2.11B |
| VCEL Vericel Corp | ▶ | $2.10B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $1.99B |
| MESO Mesoblast Ltd | ▶ | $1.79B |
| ALVO Alvotech | ▲ | $1.78B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.77B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.53B |
| IMCR Immunocore Holdings Plc | ▶ | $1.51B |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.40B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.22B |
| VOR Vor Biopharma Inc. | ▲ | $1.14B |
| REPL Replimune Group, Inc. | ▲ | $1.11B |
| JATT Zura Bio Ltd | ▶ | $994M |
| IMTX Immatics N.V. | ▲ | $957M |
| MGTX Meiragtx Holdings Plc | ▶ | $950M |
| SLBT Sl Science Holding Ltd | ▶ | $884M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $844M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $832M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $831M |
| SANA Sana Biotechnology, Inc. | ▲ | $741M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $692M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $670M |
| PRME Prime Medicine, Inc. | ▲ | $655M |
| AURA Aura Biosciences, Inc. | ▲ | $633M |
| CADL Candel Therapeutics, Inc. | ▲ | $627M |
| SLDB Solid Biosciences Inc. | ▲ | $615M |
| DBVT Dbv Technologies S.A. | ▶ | $536M |
| VALN Valneva Se | ▼ | $505M |
Where RGEN sits on the market map
Repligen Corp (RGEN) stock news
Loading...
Repligen Corp (RGEN) stock forecast FAQ
What is the Repligen Corp (RGEN) stock forecast?
On Oct. 16, 2026, RGEN is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
How accurate are Repligen Corp stock predictions?
For RGEN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 62.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 54.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Repligen Corp forecasts updated?
Repligen Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Repligen Corp's industry peers?
60 issuers in our coverage, RGEN included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.